Vascular Endothelial Growth Factor (VEGF) and its receptorVEGFR-2are key mediators of angiogenesis, making VEGFR-2 a potential targetfor antibody-drug conjugates (ADCs) in cancer treatment. This evidence concerns the gene VEGFA and cancer.